• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

October 25, 2019 by SharpBrains

_______________

As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­mote arrange­ments? (MM&M):

“San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed a co-pro­mo­tion deal.

Since the Sandoz/Pear pact was wide­ly seen as a lit­mus test of sorts for pharma’s role in help­ing dis­trib­ute this nascent tech­nol­o­gy, the com­mer­cial break-up rais­es ques­tions about the via­bil­i­ty of such part­ner­ships going for­ward. It also high­lights the par­ties’ some­times con­flict­ing pri­or­i­ties: pharma’s con­cern about its core busi­ness ver­sus dig­i­tal ther­a­peu­tics firms’ wor­ries about fund­ing and investment…

Despite the Sandoz/Pear news, he and oth­ers fore­see such col­lab­o­ra­tions con­tin­u­ing. DTx still rep­re­sents a “huge oppor­tu­ni­ty” for phar­ma, wrote Alessio Brunel­lo, senior phar­ma ana­lyst with Glob­al­Da­ta, in a note Thurs­day. DTx, he said, should see con­tin­ued part­ner­ship activ­i­ty in R&D and ther­a­peu­tics, due in part to pres­sure on health sys­tems from the aging pop­u­la­tion and increas­ing costs and in part to the poten­tial of improved adherence.

DTx can be pre­scribed as monother­a­py or togeth­er with oth­er ther­a­pies to pre­vent, man­age or treat dis­eases across diverse indi­ca­tions, par­tic­u­lar­ly chron­ic dis­eases and neu­ro­log­i­cal dis­or­ders. Pear’s reSET prod­uct, approved by the FDA in 2017, was the first soft­ware appli­ca­tion sanc­tioned for clin­i­cal use to treat sub­stance use dis­or­der (SUD) relat­ed to stim­u­lants, cannabis, cocaine and alcohol…

Pay­ers think of these solu­tions as dif­fer­ent, she (Lisa Flaiz at Bris­tol-Myers Squibb) said. “But in my opin­ion, it shouldn’t mat­ter whether it’s a pill or an app. If the out­comes are the same, the pay­ers should be pay­ing for the outcome.”

News in Context:

  • Can dig­i­tal Cog­ni­tive Behav­ioral Ther­a­py (CBTi) become the uni­ver­sal first-line treat­ment for insomnia?
  • Pear Ther­a­peu­tics rais­es $50M to devel­op and mar­ket a port­fo­lio of dig­i­tal ther­a­peu­tics for men­tal health
  • Sanofi Ven­tures leads $17M invest­ment in Click Therapeutics
  • FDA clears first CBT-based dig­i­tal ther­a­peu­tic to treat sub­stance abuse disorders
  • The FDA cre­ates new Dig­i­tal Health unit to reimag­ine reg­u­la­to­ry paths in the age of scal­able, AI-enhanced innovation
  • Five rea­sons the future of brain enhance­ment is dig­i­tal, per­va­sive and (hope­ful­ly) bright
  • The FDA warns con­sumers not to use unap­proved apps and devices to diag­nose concussion

Top Brain­no­va­tions to mon­i­tor and improve Brain Health from Sharp­Brains

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: adherence, aging-population, digital therapeutics, DTx, FDA, marketing, Novartis, Pear Therapeutics, pharma, reSET, Sandoz

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 35,212 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy